Drugs / Adipose derived mesenchymal stem cell
Adipose derived mesenchymal stem cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05308836 | May 2021 → Dec 2024 | type 1 diabetes mellitus | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02855112 | Jun 2015 → Dec 2016 | spinal muscular atrophy, type 1 | Tehran University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose-derived mesenchymal stem cell | “The purpose of this study is to evaluate the safety of intravenously (IV) administered adipose-derived mesenchymal stem cell (AD-MSC) in patients with type 1 diabetes mellitus (T1D)” NCT05308836 ↗ |
| Known as | AD-MSC | “The purpose of this study is to evaluate the safety of intravenously (IV) administered adipose-derived mesenchymal stem cell (AD-MSC) in patients with type 1 diabetes mellitus (T1D)” NCT05308836 ↗ |
| Known as | GXIPC1 | “The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors” NCT05308836 ↗ |
| Modality | Cell therapy | “cell therapy via adipose derived mesenchymal stem cells” NCT02855112 ↗ |
| Route | Intrathecal | “take stem cells intra-thecally” NCT02855112 ↗ |